VRTX
Vertex Pharmaceuticals Incorporated
Stock
$504.73−2.01 (−0.40%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.6B | $12.0B | $11.0B | $9.9B | $8.9B | $7.6B | $6.2B | $4.2B | $3.0B | $2.5B | $1.7B | $1.0B | $580M | $1.2B | $1.5B | $1.4B | $143M | $102M | $176M |
| Cost of revenue | $1.8B | $1.7B | $1.5B | $1.3B | $1.1B | $904M | $736M | $548M | $410M | $275M | $210M | $117M | $40M | $89M | $237M | $64M | $0 | — | — |
| Gross profit | $10.8B | $10.4B | $9.5B | $8.6B | $7.9B | $6.7B | $5.5B | $3.6B | $2.6B | $2.2B | $1.5B | $915M | $541M | $1.1B | $1.3B | $1.3B | $143M | — | — |
| R&D | $3.9B | $3.9B | $3.6B | $3.2B | $2.5B | $3.1B | $1.8B | $1.8B | $1.4B | $1.3B | $1.0B | $996M | $856M | $882M | $766M | $708M | $637M | $550M | $517M |
| SG&A | $2.0B | $1.8B | $1.5B | $1.1B | $945M | $840M | $771M | $659M | $558M | $496M | $433M | $377M | $305M | $356M | $433M | $401M | $188M | $130M | $101M |
| Other operating expenses | $133M | $514M | $4.6B | $476M | $58M | — | $13M | $4.5M | $29M | $270M | — | $9.6M | $72M | $495M | $45M | $125M | $14M | — | — |
| Operating income | $4.8B | $4.2B | −$233M | $3.8B | $4.3B | $2.8B | $2.9B | $1.2B | $635M | $123M | $9.9M | −$467M | −$692M | −$610M | $47M | $114M | −$696M | −$614M | −$463M |
| Non-operating income | $497M | $470M | $481M | $548M | −$75M | −$52M | $261M | $197M | −$35M | −$139M | −$77M | −$91M | −$42M | −$16M | −$15M | −$53M | −$59M | −$28M | $2.9M |
| Pretax income | $5.3B | $4.6B | $249M | $4.4B | $4.2B | $2.7B | $3.1B | $1.4B | $600M | −$16M | −$67M | −$558M | −$735M | −$626M | $32M | $60M | −$755M | −$642M | −$460M |
| Taxes | $869M | $690M | $784M | $760M | $910M | $388M | $405M | $218M | −$1.5B | −$279M | $45M | −$1.5M | $3.7M | −$181M | $139M | $31M | $0 | $0 | $0 |
| Net income | $4.4B | $4.0B | −$536M | $3.6B | $3.3B | $2.3B | $2.7B | $1.2B | $2.1B | $263M | −$112M | −$556M | −$739M | −$445M | −$107M | $30M | −$755M | −$642M | −$460M |
| Diluted EPS | $17.18 | $15.32 | −$2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 | $8.09 | $1.04 | −$0.46 | −$2.31 | −$3.14 | −$1.98 | −$0.50 | $0.14 | −$3.77 | −$3.71 | −$3.27 |
| Diluted shares | — | 258.0M | 257.9M | 260.5M | 259.1M | 259.9M | 263.4M | 260.7M | 259.2M | 253.2M | 244.7M | 241.3M | 235.3M | 224.9M | 215.3M | 208.8M | 200.4M | 173.3M | 140.6M |
| Revenue growth | — | +8.9% | +11.7% | +10.5% | +17.9% | +22.1% | +49.1% | +36.6% | +22.5% | +46.2% | +64.9% | +77.9% | −52.1% | −20.6% | +8.3% | +883.9% | +40.7% | −41.9% | — |
| Gross margin | 86.0% | 86.2% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% | 86.8% | 86.6% | 88.9% | 87.6% | 88.7% | 93.2% | 92.7% | 84.5% | 95.5% | 100.0% | — | — |
| Operating margin | 38.0% | 34.8% | −2.1% | 38.8% | 48.2% | 36.7% | 46.0% | 28.8% | 20.8% | 5.0% | 0.6% | −45.2% | −119.3% | −50.3% | 3.1% | 8.1% | −485.5% | −602.6% | −263.6% |
| Net margin | 35.0% | 32.9% | −4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | −6.6% | −53.9% | −127.2% | −36.7% | −7.0% | 2.1% | −526.3% | −630.3% | −262.0% |